Candida albicans (R303), Systemic Model (IV Infection), Kidney, CFU Data

ITEM 609035

CONTACT FOR PRICING

STATUS Available

CONTACT CUSTOMER SERVICE

^{ADD TO FAVORITES}

^{ADD TO PANEL}

OVERVIEW

DOCUMENTS/REFERENCES

RELATED SERVICES

RELATED PRODUCTS

BIOLOGICAL INFORMATION

BACKGROUND INFORMATION

This assay assesses the antimicrobial efficacy of test articles in a disseminated infection model of candidiasis and is performed with neutropenic animals. The microbial counts in kidney tissue are measured. Candida albicans is a fungus that grows as yeast and as filamentous cells and causes opportunistic oral, genital, and systemic infections of humans. Strain R303 is a human blood isolate that is susceptible to azoles, amphotericin B and echinocandins.

SPECIES

Candida albicans

ORGANISM

Fungi

INCUBATION CONDITIONS

Aerobic

ASSAY INFORMATION

ASSAY TYPE

In Vivo

TESTING INFORMATION

PROCEDURE SUMMARY

Groups of 5 neutropenic mice are used. Animals are inoculated intravenously with pathogen suspension. Test articles or vehicle are administered at time points after inoculation. Doses may be administered IV, SC, PO, IM, IP or by IV infusion. Animals are humanely euthanized with carbon dioxide asphyxiation at time points and kidneys are aseptically removed. Kidney tissue is homogenized and pathogen counts are determined by plating to agar medium. Pathogen counts from treatment groups are compared to vehicle groups and the signficance of an effect is determined.

CRITERIA FOR SIGNIFICANCE

Significant difference is determined at ≥ 2-log or P < 0.05

TURNAROUND TIME

STANDARD

20 Days

CLINICAL RELEVANCE

THERAPEUTIC AREA

Infectious Disease

ADDITIONAL INFORMATION

BRAND

PDS

TESTING LOCATION

Taiwan - Taipei

OTHER INFORMATION

We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.